Membrane complement regulatory proteins
Tóm tắt
Từ khóa
Tài liệu tham khảo
Song, 2000, Complement and innate immunity, Immunopharmacology, 49, 187, 10.1016/S0162-3109(00)80303-3
Mollnes, 2002, Complement in inflammatory tissue damage and disease, Trends Immunol., 23, 61, 10.1016/S1471-4906(01)02129-9
Walport, 2001, Complement. First of two parts, N. Engl. J. Med., 344, 1058, 10.1056/NEJM200104053441406
Hourcade, 1989, The regulators of complement activation (RCA) gene cluster, Adv. Immunol., 45, 381, 10.1016/S0065-2776(08)60697-5
Miwa, 2001, Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases, Int. Immunopharmacol., 1, 445, 10.1016/S1567-5769(00)00043-6
Lublin, 1989, Decay-accelerating factor: biochemistry, molecular biology, and function, Annu. Rev. Immunol., 7, 35, 10.1146/annurev.iy.07.040189.000343
Liszewski, 1991, Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster, Annu. Rev. Immunol., 9, 431, 10.1146/annurev.iy.09.040191.002243
Ahearn, 1989, Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21), Adv. Immunol., 46, 183, 10.1016/S0065-2776(08)60654-9
Spicer, 1995, Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes. Duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms, J. Immunol., 155, 3079, 10.4049/jimmunol.155.6.3079
Song, 1996, Mouse decay-accelerating factor: selective and tissue-specific induction by estrogen of the gene encoding the glycosylphosphatidylinositol-anchored form, J. Immunol., 157, 4166, 10.4049/jimmunol.157.9.4166
Powell, 1997, Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59, J. Immunol., 158, 1692, 10.4049/jimmunol.158.4.1692
Qian, 2000, Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59, J. Immunol., 165, 2528, 10.4049/jimmunol.165.5.2528
Cole, 1985, Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines, Proc. Natl. Acad. Sci. U. S. A., 82, 859, 10.1073/pnas.82.3.859
Nickells, 1990, Characterization of CR1- and membrane cofactor protein-like proteins of two primates, J. Immunol., 144, 4262, 10.4049/jimmunol.144.11.4262
Johnstone, 1993, Identification and quantification of complement regulator CD46 on normal human tissues, Immunology, 79, 341
Miwa, 1998, Molecular cloning of rat and mouse membrane cofactor protein (MCP, CD46): preferential expression in testis and close linkage between the mouse Mcp and Cr2 genes on distal chromosome 1, Immunogenetics, 48, 363, 10.1007/s002510050447
Holers, 1992, The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function, Immunol. Today, 13, 231, 10.1016/0167-5699(92)90160-9
Li, 1993, Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF, J. Immunol., 151, 4295, 10.4049/jimmunol.151.8.4295
Paul, 1989, The murine complement receptor gene family. Analysis of mCRY gene products and their homology to human CR1, J. Immunol., 142, 582, 10.4049/jimmunol.142.2.582
Song, 2004, Membrane complement regulatory proteins in autoimmune and inflammatory tissue injury, Curr. Dir. Autoimmun., 7, 181, 10.1159/000075693
Goodfellow, 2000, Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis, Clin. Exp. Immunol., 119, 210, 10.1046/j.1365-2249.2000.01129.x
Mizuno, 2000, Comparison of the suppressive effects of soluble CR1 and C5a receptor antagonist in acute arthritis induced in rats by blocking of CD59, Clin. Exp. Immunol., 119, 368, 10.1046/j.1365-2249.2000.01127.x
Hamacher, 1998, Soluble complement receptor type 1 (CD35) in bronchoalveolar lavage of inflammatory lung diseases, Eur. Respir. J., 11, 112, 10.1183/09031936.98.11010112
Mulligan, 1999, Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewisx moieties, J. Immunol., 162, 4952, 10.4049/jimmunol.162.8.4952
Molina, 1990, A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2, J. Immunol., 145, 2974, 10.4049/jimmunol.145.9.2974
Kinoshita, 1988, Monoclonal antibodies to mouse complement receptor type 1 (CR1). Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative, J. Immunol., 140, 3066, 10.4049/jimmunol.140.9.3066
Holers, 2004, Complement receptor 2 and autoimmunity, Curr. Dir. Autoimmun., 7, 33, 10.1159/000075686
Nicholson-Weller, 1983, Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor, Proc. Natl. Acad. Sci. U. S. A., 80, 5066, 10.1073/pnas.80.16.5066
Pangburn, 1983, Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria, Proc. Natl. Acad. Sci. U. S. A., 80, 5430, 10.1073/pnas.80.17.5430
Pangburn, 1983, Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes, J. Exp. Med., 157, 1971, 10.1084/jem.157.6.1971
Rosse, 1985, Paroxysmal nocturnal haemoglobinuria, Clin. Haematol., 14, 105, 10.1016/S0308-2261(21)00464-1
Parker, 2005, Diagnosis and management of paroxysmal nocturnal hemoglobinuria, Blood, 3699, 10.1182/blood-2005-04-1717
Miyata, 1994, Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria, N. Engl. J. Med., 330, 249, 10.1056/NEJM199401273300404
Telen, 1989, The Inab phenotype: characterization of the membrane protein and complement regulatory defect, Blood, 74, 437, 10.1182/blood.V74.1.437.437
Lublin, 1994, Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes, Blood, 84, 1276, 10.1182/blood.V84.4.1276.1276
Yamashina, 1990, Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria, N. Engl. J. Med., 323, 1184, 10.1056/NEJM199010253231707
Shichishima, 1999, Complement sensitivity of erythrocytes in a patient with inherited complete deficiency of CD59 or with the Inab phenotype, Br. J. Haematol., 104, 303, 10.1046/j.1365-2141.1999.01188.x
Miwa, 2002, Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack, Blood, 99, 3707, 10.1182/blood.V99.10.3707
Sun, 1999, Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting, Proc. Natl. Acad. Sci. U. S. A., 96, 628, 10.1073/pnas.96.2.628
Holt, 2001, Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria, Blood, 98, 442, 10.1182/blood.V98.2.442
Fossati-Jimack, 1999, High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia, J. Exp. Med., 190, 1689, 10.1084/jem.190.11.1689
Molina, 2002, Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor, Blood, 100, 4544, 10.1182/blood-2002-06-1875
Telen, 1988, Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF, J. Exp. Med., 167, 1993, 10.1084/jem.167.6.1993
Kraus, 2000, A direct comparison of complement inhibitory capacities of the GPI- and transmembrane forms of mouse DAF to mouse Crry and human rsCR1, Immunopharmacology, 49, 64, 10.1016/S0162-3109(00)80182-4
Riley-Vargas, 2004, CD46: expanding beyond complement regulation, Trends Immunol., 25, 496, 10.1016/j.it.2004.07.004
Daha, 1993, The possible role of membrane complement regulators in vasculitis, Behring Inst. Mitt., 184
Diaz, 2005, The serum level of xenoantibodies, and hDAF or alphaGAL expression on pig cells, modulate in vitro the protection given by hDAF to primate complement-mediated damage, Transplant Proc., 37, 510, 10.1016/j.transproceed.2005.02.020
Holzknecht, 1999, Identification of antigens on porcine pulmonary microvascular endothelial cells recognized by human xenoreactive natural antibodies, Lab. Invest., 79, 763
Banz, 2005, Endothelial cell protection and complement inhibition in xenotransplantation: a novel in vitro model using whole blood, Xenotransplantation, 12, 434, 10.1111/j.1399-3089.2005.00239.x
Fecke, 2002, Protection of hDAF-transgenic porcine endothelial cells against activation by human complement: role of the membrane attack complex, Xenotransplantation, 9, 97, 10.1034/j.1399-3089.2002.1o012.x
Loveland, 2004, Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons, Xenotransplantation, 11, 171, 10.1046/j.1399-3089.2003.00103_11_2.x
Menoret, 2004, Characterization of human CD55 and CD59 transgenic pigs and kidney xenotransplantation in the pig-to-baboon combination, Transplantation, 77, 1468, 10.1097/01.TP.0000111758.35048.EA
Schmoeckel, 1997, Xenotransplantation of pig organs transgenic for human DAF: an update, Transplant Proc., 29, 3157, 10.1016/S0041-1345(97)00823-3
Schmoeckel, 1997, Transgenic human decay accelerating factor makes normal pigs function as a concordant species, J. Heart Lung Transplant, 16, 758
Fodor, 1994, Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection, Proc. Natl. Acad. Sci. U. S. A., 91, 11153, 10.1073/pnas.91.23.11153
Ahmad, 2003, Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition, Immunology, 110, 258, 10.1046/j.1365-2567.2003.01733.x
Mason, 2001, Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis, Arthritis Rheum., 44, 138, 10.1002/1529-0131(200101)44:1<138::AID-ANR18>3.0.CO;2-G
Mason, 1999, Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition, Blood, 94, 1673, 10.1182/blood.V94.5.1673
Griselli, 1999, C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction, J. Exp. Med., 190, 1733, 10.1084/jem.190.12.1733
Yeh, 2003, Coming of age of C-reactive protein: using inflammation markers in cardiology, Circulation, 107, 370, 10.1161/01.CIR.0000053731.05365.5A
Bhakdi, 1999, Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation, Arterioscler., Thromb., Vasc. Biol., 19, 2348, 10.1161/01.ATV.19.10.2348
Wolbink, 1996, CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes, J. Immunol., 157, 473, 10.4049/jimmunol.157.1.473
Niculescu, 1999, Complement activation and atherosclerosis, Mol. Immunol., 36, 949, 10.1016/S0161-5890(99)00117-0
Li, 2004, C-reactive protein upregulates complement-inhibitory factors in endothelial cells, Circulation, 109, 833, 10.1161/01.CIR.0000117087.27524.0E
Weitz-Schmidt, 2002, Statins as anti-inflammatory agents, Trends Pharmacol. Sci., 23, 482, 10.1016/S0165-6147(02)02077-1
Mason, 2002, Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury, Circ. Res., 91, 696, 10.1161/01.RES.0000038151.57577.19
Qin, 2004, Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes, Diabetes, 53, 2653, 10.2337/diabetes.53.10.2653
Acosta, 2000, Molecular basis for a link between complement and the vascular complications of diabetes, Proc. Natl. Acad. Sci. U. S. A., 97, 5450, 10.1073/pnas.97.10.5450
Davies, 2005, Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects, Immunology, 114, 280, 10.1111/j.1365-2567.2004.02086.x
Semple, 2005, Autoimmune pathogenesis and autoimmune hemolytic anemia, Semin. Hematol., 42, 122, 10.1053/j.seminhematol.2005.04.002
Walport, 2001, Complement. Second of two parts, N. Engl. J. Med., 344, 1140, 10.1056/NEJM200104123441506
Miwa, 2002, Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice, Am. J. Pathol., 161, 1077, 10.1016/S0002-9440(10)64268-X
Cohen, 1991, Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease, Annu. Rev. Immunol., 9, 243, 10.1146/annurev.iy.09.040191.001331
Cohen, 1992, The lpr and gld genes in systemic autoimmunity: life and death in the Fas lane, Immunol. Today, 13, 427, 10.1016/0167-5699(92)90066-G
Mead, 2004, Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis, Lab. Invest., 84, 21, 10.1038/labinvest.3700015
Liu, 2005, The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo, J. Exp. Med., 201, 567, 10.1084/jem.20040863
Heeger, 2005, Decay-accelerating factor modulates induction of T cell immunity, J. Exp. Med., 201, 1523, 10.1084/jem.20041967
Schrijver, 1990, Anti-GBM nephritis in the mouse: role of granulocytes in the heterologous phase, Kidney Int., 38, 86, 10.1038/ki.1990.171
Sogabe, 2001, Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis, J. Immunol., 167, 2791, 10.4049/jimmunol.167.5.2791
Arumugam, 2004, The role of the complement system in ischemia–reperfusion injury, Shock, 21, 401, 10.1097/00024382-200405000-00002
Lien, 2003, Pathogenesis of renal ischemia/reperfusion injury: lessons from knockout mice, Life Sci., 74, 543, 10.1016/j.lfs.2003.08.001
Rossen, 1994, Cardiolipin–protein complexes and initiation of complement activation after coronary artery occlusion, Circ. Res., 75, 546, 10.1161/01.RES.75.3.546
Entman, 1991, Inflammation in the course of early myocardial ischemia, FASEB J., 5, 2529, 10.1096/fasebj.5.11.1868978
Collard, 2001, Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1, Am. J. Pathol., 159, 1045, 10.1016/S0002-9440(10)61779-8
Austen, 2003, The role of complement and natural antibody in intestinal ischemia–reperfusion injury, Int. J. Immunopathol. Pharmacol., 16, 1, 10.1177/039463200301600101
Chan, 2003, Ischaemia–reperfusion is an event triggered by immune complexes and complement, Br. J. Surg., 90, 1470, 10.1002/bjs.4408
Fleming, 2004, Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice, J. Immunol., 173, 7055, 10.4049/jimmunol.173.11.7055
Fleming, 2002, Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire, J. Immunol., 169, 2126, 10.4049/jimmunol.169.4.2126
Yamada, 2004, Critical protection from renal ischemia reperfusion injury by CD55 and CD59, J. Immunol., 172, 3869, 10.4049/jimmunol.172.6.3869
Turnberg, 2004, CD59a deficiency exacerbates ischemia–reperfusion injury in mice, Am. J. Pathol., 165, 825, 10.1016/S0002-9440(10)63345-7
Richards, 2003, Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome, Proc. Natl. Acad. Sci. U. S. A., 100, 12966, 10.1073/pnas.2135497100
Noris, 2003, Familial haemolytic uraemic syndrome and an MCP mutation, Lancet, 362, 1542, 10.1016/S0140-6736(03)14742-3
Rooney, 1992, Membrane attack complex (MAC)-mediated damage to spermatozoa: protection of the cells by the presence on their membranes of MAC inhibitory proteins, Immunology, 75, 499
Vanderpuye, 1992, The complement system in human reproduction, Am. J. Reprod Immunol., 27, 145, 10.1111/j.1600-0897.1992.tb00742.x
Oglesby, 1996, Human complement regulator expression by the normal female reproductive tract, Anat. Rec., 246, 78, 10.1002/(SICI)1097-0185(199609)246:1<78::AID-AR9>3.0.CO;2-B
Harris, 1999, Molecular and functional analysis of mouse decay accelerating factor (CD55), Biochem. J., 341, 821, 10.1042/0264-6021:3410821
Holt, 2000, Genomic structure and chromosome location of the gene encoding mouse CD59, Cytogenet. Cell Genet., 89, 264, 10.1159/000015630
Wang, 1998, Molecular cloning and characterization of decay-accelerating factor deficiency in Cromer blood group Inab phenotype, Blood, 91, 680, 10.1182/blood.V91.2.680
Matthes, 2002, Acquired and transient RBC CD55 deficiency (Inab phenotype) and anti-IFC, Transfusion, 42, 1448, 10.1046/j.1537-2995.2002.00214.x
Qin, 2003, Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility, Immunity, 18, 217, 10.1016/S1074-7613(03)00022-0
Baalasubramanian, 2004, CD59a is the primary regulator of membrane attack complex assembly in the mouse, J. Immunol., 173, 3684, 10.4049/jimmunol.173.6.3684
Simpson, 1994, Differential expression of complement regulatory proteins decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 during human spermatogenesis, Immunology, 81, 452
Riley-Vargas, 2005, Targeted and restricted complement activation on acrosome-reacted spermatozoa, J. Clin. Invest., 115, 1241, 10.1172/JCI23213
Kurita-Taniguchi, 2002, Molecular assembly of CD46 with CD9, alpha3-beta1 integrin and protein tyrosine phosphatase SHP-1 in human macrophages through differentiation by GM-CSF, Mol. Immunol., 38, 689, 10.1016/S0161-5890(01)00100-6
Nomura, 2001, Genomic analysis of idiopathic infertile patients with sperm-specific depletion of CD46, Exp. Clin. Immunogenet., 18, 42, 10.1159/000049086
Inoue, 2003, Disruption of mouse CD46 causes an accelerated spontaneous acrosome reaction in sperm, Mol. Cell. Biol., 23, 2614, 10.1128/MCB.23.7.2614-2622.2003
Xu, 2000, A critical role for murine complement regulator crry in fetomaternal tolerance, Science, 287, 498, 10.1126/science.287.5452.498
Mao, 2003, Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway, Immunity, 19, 813, 10.1016/S1074-7613(03)00321-2
Miwa, 2001, Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity, Immunology, 104, 207, 10.1046/j.1365-2567.2001.01280.x
Holers, 2002, Complement C3 activation is required for antiphospholipid antibody-induced fetal loss, J. Exp. Med., 195, 211, 10.1084/jem.200116116
Rehrig, 2001, Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice, J. Immunol., 167, 5921, 10.4049/jimmunol.167.10.5921
Quigg, 1998, Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor, J. Immunol., 160, 4553, 10.4049/jimmunol.160.9.4553
Weisman, 1990, Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis, Science, 249, 146, 10.1126/science.2371562
Weisman, 1990, Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium, Trans. Assoc. Am. Physicians, 103, 64
Sugita, 1994, Recombinant soluble CD59 inhibits reactive haemolysis with complement, Immunology, 82, 34
Fraser, 2003, Generation of a recombinant, membrane-targeted form of the complement regulator CD59: activity in vitro and in vivo, J. Biol. Chem., 278, 48921, 10.1074/jbc.M302598200
Harris, 2002, Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo, Clin. Exp. Immunol., 129, 198, 10.1046/j.1365-2249.2002.01924.x
Zhang, 1999, Targeting of functional antibody-CD59 fusion proteins to a cell surface, J. Clin. Invest., 103, 55, 10.1172/JCI4607
He, 2005, Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9, J. Immunol., 174, 5750, 10.4049/jimmunol.174.9.5750